second-generation anti-CALR CAR T-cell therapy (University College London/Weatherall Institute of Molecular Medicine)

N/A

Report date: 2025/06/11 11:25:34

Base Information

Drug Namesecond-generation anti-CALR CAR T-cell therapy (University College London/Weatherall Institute of Molecular Medicine)
Drug Alias Nameanti-CALR CAR T-cell therapy (University College London/Weatherall Institute of Molecular Medicine)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsCalreticulin modulators
TargetsCalreticulin
Therapy Area/IndicationsMyeloproliferative DisordersHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesMRC Weatherall Institute of Molecular MedicineUniversity College London
Inactive CompaniesN/A
Active IndicationsMyeloproliferative DisordersHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A